Patents Assigned to Nippon Chemiphar Co., Ltd.
  • Publication number: 20210364503
    Abstract: Provided is a biochemical reaction substrate which can achieve higher test sensitivity and shorter testing time in an allergy test, which can also reduce a required amount of blood or the like needed as a specimen and decrease the number of test steps, thereby facilitating performance of the test, and which is to be used in an allergy test in which infection risk of the test staff is reduced.
    Type: Application
    Filed: February 1, 2019
    Publication date: November 25, 2021
    Applicants: NIPPON CHEMIPHAR CO., LTD., UEDA JAPAN RADIO CO., LTD.
    Inventors: Kenji UEMURA, Norio TANIMOTO, Mai EGAMI, Takahiro MATAKI, Yumi KONISHI, Motoe SHIMIZU, Shigenori TAKAHASHI, Koji SAKAGUCHI
  • Publication number: 20210353575
    Abstract: The present invention provides a food composition or pharmaceutical composition which includes, as an active ingredient, citric acid or a salt thereof. Ingestion or administration of the food composition or pharmaceutical composition leads to suppression of alcohol sickness or hangover due to alcoholic beverage ingestion; suppression of an increase in blood alcohol level, an increase in blood acetaldehyde level, or an increase in blood acetic acid level due to alcoholic beverage ingestion; suppression of a decrease in blood pyruvic acid level due to alcoholic beverage ingestion; suppression of an abnormal blood lactic acid/pyruvic acid ratio due to alcoholic beverage ingestion; suppression of an increase in blood alcohol level immediately after alcohol ingestion; suppression of alcohol absorption; promotion of alcohol metabolism; or an increase in blood ornithine level, blood serotonin level, blood taurine level, blood cystine level, or blood nicotine amide level.
    Type: Application
    Filed: October 16, 2019
    Publication date: November 18, 2021
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Kazuhiko KAWAGUCHI, Satomi YAMASAKI
  • Publication number: 20210205326
    Abstract: The present invention relates to a medicine for preventing or treating pain in nociceptive pain, inflammatory pain, or neuropathic pain, the medicine comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action, a tautomer of the compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The medicine has no effect on driving or machine operation ability, has no effect on car driving ability, does not require any restriction to administration thereof to a patient engaging in operation of a dangerous machine including driving a car, or can be administered to a patient engaging in operation of a dangerous machine including driving a car.
    Type: Application
    Filed: September 3, 2019
    Publication date: July 8, 2021
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventor: Toshiyasu IMAI
  • Publication number: 20210196747
    Abstract: Provided is a metabolism improving agent that contains, for example, an alkalizing agent such as an acidosis improving agent or a urinary alkalizing agent as an active ingredient, and has actions such as improvement of insulin resistance, improvement of pituitary and adrenal functions, and reduction of visceral fat accumulation.
    Type: Application
    Filed: May 24, 2019
    Publication date: July 1, 2021
    Applicants: University of the Ryukyus, Nippon Chemiphar Co., Ltd.
    Inventors: Hiroaki MASUZAKI, Hideki NAKAMURA, Toshitake HIRAI, Kaoru HARA, Takashi KANDA, Satomi YAMASAKI, Tadashi KOBAYASHI, Koichiro NISHIOKA
  • Patent number: 10995092
    Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and Rio, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: May 4, 2021
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi Nagase, Eriko Nakata, Masaaki Hirose, Isao Ooi
  • Publication number: 20210121426
    Abstract: The present invention relates to a food composition comprising an alkalinizing agent, particularly an alkali metal salt of citric acid. Ingestion of the food composition maintains kidney function.
    Type: Application
    Filed: March 13, 2018
    Publication date: April 29, 2021
    Applicants: TOHOKU UNIVERSITY, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Michiaki ABE, Seizo KOSHIBA, Koichiro NISHIOKA, Kazuhiko KAWAGUCHI, Satomi YAMASAKI, Yasuyuki TERANAKA
  • Publication number: 20210040094
    Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R9 represent hydrogen, etc.; R9 and R10, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Application
    Filed: October 13, 2020
    Publication date: February 11, 2021
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Publication number: 20210000840
    Abstract: The present invention pertains to a medicament for preventing or treating cough, including, as an active ingredient, a compound having P2X4 receptor antagonistic action, a tautomer, stereoisomer, or pharmaceutically acceptable salt of the compound, or a hydrate or solvate thereof.
    Type: Application
    Filed: March 14, 2019
    Publication date: January 7, 2021
    Applicants: NIPPON CHEMIPHAR CO., LTD., HOSHI UNIVERSITY
    Inventors: Toshiyasu IMAI, Junzo KAMEI
  • Publication number: 20200223806
    Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 16, 2020
    Applicant: NIPPON CHEMIPHAR CO., LTD
    Inventors: Masatoshi USHIODA, Kunio KOBAYASHI, Daisuke SAITO, Shogo SAKUMA, Toshiyasu IMAI, Kazuhide INOUE
  • Patent number: 10660882
    Abstract: The present invention provides a prophylactic or therapeutic agent for giant cell tumors occurring in a bone and soft tissue or for chondrosarcoma, which comprises a non-steroidal anti-inflammatory agent or thiazolidine derivative as an active ingredient, and the like.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: May 26, 2020
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya
  • Patent number: 10653667
    Abstract: The present invention provides an agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis of giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma, a local infusion for artery embolization, and an artificial bone, which comprises a substance having a PPAR?-agonistic activity and/or a PPAR? expression-inducing activity as an active ingredient. The agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis, the local infusion for artery embolization, and the artificial bone of the present invention are a radical therapeutic agent or radical therapeutic material that can cause apoptosis in giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma to make the tumor disappear, and can induce differentiation of the tumor into fat cells to make the tumor disappear.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 19, 2020
    Assignee: NIPPON CHEMIPHAR CO., LTD
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya
  • Patent number: 10633349
    Abstract: The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(?O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(?O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(?O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: April 28, 2020
    Assignee: NIPPON CHEMIPHAR CO., LTD
    Inventors: Masatoshi Ushioda, Kunio Kobayashi, Daisuke Saito, Shogo Sakuma, Toshiyasu Imai, Kazuhide Inoue
  • Publication number: 20200079775
    Abstract: A morphinan derivative represented by the following general formula (I): wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc.; R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group; Y binds to a carbon atom as a ring-constituting atom of R2; R3, R4, and R5 represent hydrogen, hydroxy, etc.; R6a and R6b represent hydrogen, etc.; R7 and R8 represent hydrogen, etc.; R9 and Rio, which are the same or different, represent hydrogen, etc.; X represents O or CH2; and Y represents C(?O)); a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Application
    Filed: July 19, 2019
    Publication date: March 12, 2020
    Applicant: NIPPON CHEMIPHAR CO., LTD
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Patent number: 10472333
    Abstract: Compounds represented by the following general formula (I), which has a P2X4 receptor antagonistic activity (in the formula, R1, R2 and R3 represent hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a halogen atom, and the like, X represents C or N, Y represents N or C(?O), provided that when X is C, Y represents N, and when X is N, Y represents C(?O), the double line consisting of the solid line and the broken line represents a single bond or double bond, n represents an integer of 0 to 6, Z represents O, S, or an atomic bond, and A represents benzene ring, pyridine ring, and the like).
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: November 12, 2019
    Assignees: NIPPON CHEMIPHAR CO., LTD., KYUSHU UNIVERSITY
    Inventors: Shogo Sakuma, Kunio Kobayashi, Masatoshi Ushioda, Toshiyasu Imai, Kazuhide Inoue
  • Publication number: 20190328725
    Abstract: The present invention relates to a pharmaceutical composition comprising a morphinan derivative that exhibits an opioid ? receptor agonist activity. By administering the pharmaceutical composition provided by the present invention, opioid ? receptor related diseases (for example, headache) can be treated or prevented.
    Type: Application
    Filed: September 15, 2017
    Publication date: October 31, 2019
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi NAGASE, Hideaki FUJII, Akiyoshi SAITOH, Eriko NAKATA, Masaaki HIROSE, Isao OOI, Kohei HAYASHIDA
  • Patent number: 10442802
    Abstract: A morphinan derivative represented by the following general formula (I): (wherein R1 represents hydrogen, C1-10 alkyl, cycloalkylalkyl where the cycloalkyl moiety has 3 to 6 carbon atoms, and the alkylene moiety has 1 to 5 carbon atoms, etc., R2 represents heterocyclic ring containing 1 to 4 heteroatoms selected from N, O and S and at least one carbon atom as ring-constituting atoms, containing at least one set of adjacent ring-constituting atoms bound by a double bond, and further substituted with at least one oxo group, Y binds to a carbon atom as a ring-constituting atom of R2, R3, R4, and R5 represent hydrogen; hydroxy, etc., R6a and R6b represent hydrogen, etc., R7 and R8 represent hydrogen, etc., R9 and R10, which are the same or different, represent hydrogen, etc., X represents O or CH2, and Y represents C(?O)), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt thereof, or a solvate thereof is used as an anxiolytic drug, antidepressant, etc.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: October 15, 2019
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Hiroshi Nagase, Hideaki Fujii, Akiyoshi Saitoh, Eriko Nakata, Masaaki Hirose, Isao Ooi, Kohei Hayashida
  • Patent number: 10413546
    Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 17, 2019
    Assignees: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, NIPPON MEDICAL SCHOOL FOUNDATION, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Takeshi Nishino, Shinsuke Kato, Masako Kato, Hidenori Suzuki, Ken Okamoto
  • Publication number: 20190255022
    Abstract: A wound-healing agent is provided by using a benzisoxazole compound represented by the following general formula (I), a tautomer, a stereoisomer, or a pharmaceutically acceptable salt of the compound, a solvate of any of the foregoing, or the like, which exerts a PPAR? agonist effect.
    Type: Application
    Filed: May 11, 2017
    Publication date: August 22, 2019
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Toshitake HIRAI, Takaichi HAMANO, Tomio YAMAKAWA
  • Publication number: 20190192510
    Abstract: A compound represented by the following formula (I) or the formula (II) disclosed in the specification is a GPR119 agonist, and is used as an agent for treating diabetes: wherein one of T1, T2, T3, and T4 is N, and each of the other three independently is CR4 or, in the alternative, each of the four independently is CR4; each of R2 and R3 is hydrogen or a C1-8 alkyl group; the double line consisting of a solid line and a broken line means a single or double bond; A is (CH2)m, a bond, or the like; B is (C(R5)H)n, a bond, or the like; one of U and V is N, and the other is CR7; W is C or CR8; each of X and Y is a C1-3 alkylene group, which optionally has a halogen atom, hydroxyl etc.; Z is C(O)OR9, C(O)R10, or the like.
    Type: Application
    Filed: February 1, 2011
    Publication date: June 27, 2019
    Applicant: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Tsuyoshi ENDO, Rie TAKAHASHI, Hiroto TANAKA, Toshihiro KUNIGAMI
  • Patent number: 10292974
    Abstract: The present invention provides a prophylactic or therapeutic agent for giant cell tumors occurring in a bone and soft tissue or for chondrosarcoma, which comprises a non-steroidal anti-inflammatory agent or thiazolidine derivative as an active ingredient, and the like.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: May 21, 2019
    Assignee: NIPPON CHEMIPHAR CO., LTD.
    Inventors: Akihiko Takeuchi, Hiroyuki Tsuchiya